Amir London assumed responsibility as Kamada’s CEO in July 2015.
Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience.
Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm’s global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Chaime Orlev is serving as our Chief Financial Officer since December 2017. Prior to joining us, he served as Chief Financial Officer and VP Finance and Administration of Bioblast Pharma Ltd (NASDAQ:ORPN) from 2016 to 2017. Prior to that, Mr. Orlev served in various finance positions, in the biotech industry, including VP Finance and Administration of Chiasma Inc. (NASDAQ: CHMA), Chief Financial Officer of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), and Chief Financial Officer of Gammacan Inc. Mr. Orlev also served as VP Finance and Chief Financial Officer of Huntleigh USA Corporation. Mr. Orlev received his M.B.A. from the Leon Recanati Graduate School of Business Administration at the Tel Aviv University and a B.A. in Business Administration from the College of Business in Israel. Mr. Orlev is a Certified Public Accountant under the laws of the state of Israel.
Eran Nir serves as our Chief Operating Officer since March 2022, before that he was our VP Operations. Mr. Nir has over 14 years of operation management experience in the pharmaceutical and medical industries. His recent roles include management of TEVA’s Pharmaceutical plant in Jerusalem, VP Operations of Emilia Cosmetics and management of a medical equipment plant of Philips Medical Systems. Mr. Nir’s extensive experience spans across the management of large scale FDA and EMA- approved manufacturing facilities, tech-transfer of new products from development to production and the implementation of world-class operational excellence systems.
Mr. Nir has B.SC degree in Industrial Engineering and M.B.A. both from Ben Gurion University.
Hanni Neheman serves as Kamada’s Marketing & Sales Vice President since January 2020.
Mrs. Neheman joined Kamada in August 2014 and served as the Head of Business Operations for the Israeli market.
Mrs. Neheman has more than 20 years of experience in different positions in the field of Marketing & Sales in the pharmaceutical industry.
Prior to joining us, she served as a Commercial Manager at Neopharm Israel.
Mrs. Neheman holds a BA degree in Occupational Therapy from Haifa University & Technion, Haifa, and Executive M.B.A from Derby University.
Mr Knight serves as Kamada’s Vice President of US Commercial Operations. He joined the company in March 2022 with nearly 25 years of Life Sciences experiences, primarily focusing on commercializing innovative specialty plasma-products.
Prior to joining Kamada, Mr. Knight served in a variety of commercial leadership positions. Most recently Mr. Knight was responsible for Trade Relations at TherapeuticsMD successfully launching three innovative products into the market. Mr. Knight’s professional background also includes leadership positions at Prometic Life Sciences, CIS by Deloitte, Cardinal Health, Cangene bioPharma and Nabi bioPharmaceuticals. Mr. Knight received an MBA from Colorado State University and a B.A. in Biology from Colorado Mesa University.
Orit Pinchuk has served as our Vice President, Regulatory Affairs since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities.
Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.
Ariella Raban serves as Kamada’s Vice President, Human Resources since May 2018.
Mrs. Raban joined Kamada in March 2014 and served as Human Resources Manager for Kamada’s manufacturing site. Mrs. Raban has more than a decade of expertise in different positions in the field of HR in the pharmaceutical industry.
Prior to joining us, she served as a Human Resources Manager at Teva Pharmaceuticals.
Mrs. Raban holds a BA degree in Humanities Social Science from Ben-Gurion University.
Yael Brenner has served as our Vice President Quality since March 2015. Mrs. Yael Brenner has experience of more than 20 years in Quality Management, including QA and QC managerial positions in the pharmaceutical industry. Prior to her joining Kamada, her last position in Teva Pharmaceuticals Industries was Senior Director Quality Operations of Teva Kfar Saba Site, managing over 400 workers in QA, QC and RA. Mrs. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion, Haifa, and in addition Certified Quality Engineer (CQE) from the American and the Israeli and Societies for Quality.
Ms. Philip serves as our VP, General Counsel and Corporate Secretary since October 2020.
Ms. Philip has been practicing law for more than 15 years, with an experience of over a decade in the BioMed industry. Prior to joining Kamada, she served as VP Legal Affairs and Compliance Officer of OPKO Biologics, a sub of OPKO Health (NASDAQ:OPK), responsible for all company’s legal matters and commercial agreements including IP licensing, R&D collaborations, clinical trials and drug manufacturing contracts. Ms. Philip has vast experience from leading law firms on international biotech M&A deals, joint ventures and commercial transactions. Prior to that, she worked at the Israel Securities Authorities, the Department of Economics and Fiscal Law of the State Attorney, Israel.
Ms. Philip is a member of the Israel Bar Association. She holds an LLB cum laude and a Bachelor’s Degree in Economics from Haifa University; Master cum laude in Law and Economics from Erasmus University in the Netherlands in collaboration with Berkeley University, USA; and an MBA from the Technion-Israel Institute of Technology, Israel.
Ms. Philip also serves as a member of the board of directors of the Israeli Association of Corporate Counsels and head of the ACC BioMed Forum.
Shavit Beladev serves as Vice President, Kamada Plasma, since June 2022, responsible for the operations and expansion of the Company’s wholly owned U.S-based plasma collection subsidiary. Ms. Beladev has been with Kamada for over 20 years in increasingly senior positions, most recently as Director of Business Development. Prior to that she served in management roles at the Company, responsible for International Sales, Key Accounts Management and Plasma Procurement. Since the establishment of Kamada Plasma in early 2021, Ms. Beladev’s extended responsibilities also included overseeing the operation of the Company’s plasma collection center in Beaumont, Texas, and the advance towards the opening of new U.S-based centers. Ms. Beladev holds a BA degree in Economics and Business Administration from Ben-Gurion University, Israel.
Boris Gorelik is serving as our Vice President, Business Development and Strategic Programs, since June 2022. Mr. Gorelik joined Kamada in April 2020 and served as Business Development Director. He has over 14 years of Business Development and M&A experience, most of it in the pharmaceutical industry. Prior to joining Kamada his last position was Senior Director Corporate Business Development at Teva Pharmaceuticals. Prior to that, Mr. Gorelik served in various legal, M&A, and transaction services positions in Goldfarb Seligman law offices, KPMG and Deloitte. Mr. Gorelik holds MBA, Bachelor of Laws (LLB) and B.A in accounting, all from Tel-Aviv University, Israel.
Lilach Asher Topilsky has served as a member of our board of directors since December 2019, as the Chairman of our board of directors since August 2020, and serves as a member of our Compensation Committee and Strategy Committee. Mrs. Asher Topilsky has been a Senior Partner in the FIMI Opportunity Funds, Israel’s largest group of private equity funds, since December 2019. Mrs. Asher Topilsky currently serves as the chairman of G1 Security Systems Ltd. (TASE), Rimoni Industries Ltd. (TASE), SOS Ltd. and Elyakim Ben Ari Group Ltd. and as a director at Amiad Water Systems Ltd. (AIM) and Tel Aviv University. Prior to joining FIMI, Mrs. Asher Topilsky served as the President and CEO of Israel Discount Bank (TASE), one of the leading banking groups in Israel, as the Chairman at IDBNY BANKCORP and as a director at IDB Bank New York from 2014 -2019. Mrs. Asher Topilsky also served as the Chairman of Mercantile Bank from 2014-2016. Before that, Mrs. Asher Topilsky served as a member of the management of Bank Hapoalim (TASE) as Deputy CEO & Head of Retail Banking Division (2009-2013) & Head of Strategy & Planning Division (2007-2009). Mrs. Asher Topilsky served as a Strategy Consultant at The Boston Consulting Group (BCG, Chicago 1997-1998) and at Shaldor Strategy Consulting (Israel 1995-1996). Mrs. Asher Topilsky holds an M.B.A. degree from Kellogg School of Management, Northwestern University, Chicago, USA (1997), and a B.A. degree in Management and Economics from Tel Aviv University, Israel (Magna Cum Laude, 1994).
Amiram Boehm has served on our board of directors since December 2019 and serves as a member of our Strategy Committee. Mr. Boehm is a Partner in the FIMI Opportunity Funds, Israel’s largest group of private equity funds, since 2004. Mr. Boehm served as the Managing Partner and Chief Executive Officer of FITE GP (2004), and serves as a director at Gilat Satellite Communications (NASDAQ), Hadera Paper Ltd. (TASE), Rekah Pharmaceuticals Ltd. (TASE), TAT Technologies Ltd. (NASDAQ, TASE), PCB Technologies Ltd. (TASE), GreenStream Ltd. and Galam Ltd. Mr. Boehm previously served as a director of DIMAR Ltd., Ormat Technologies Inc. (NYSE, TASE), Scope Metal Trading Ltd. (TASE), Inter Industries, Ltd. (TASE), Global Wire Ltd. (TASE), Telkoor Telecom Ltd. (TASE), Solbar Industries Ltd. (previously traded on the TASE), Ham-Let (Israel-Canada) Ltd. (TASE) and Novolog Ltd (TASE). Prior to joining FIMI, from 1999 until 2004, Mr. Boehm served as Head of Research of Discount Capital Markets, the investment arm of Israel Discount Bank. Mr. Boehm holds a B.A. degree in Economics, an LL.B degree from Tel Aviv University and a Joint M.B.A. degree from Northwestern University and Tel Aviv University.
Prof. Ari Shamiss has served on our board of directors since August 2020 and serves as a member of our Audit Committee. Prof. Shamiss is the Founder, General Partner and Chairman of the Investment Committee at Assuta Life Sciences Ventures, a life sciences-focused venture capital entity. Prior to that, from September 2016 to June 2020, Prof. Shamiss served as CEO of Assuta Medical Centers, the largest private hospital network in Israel, which includes eight hospitals and medical centers, with over $600 million in annual revenue. From July 2005 to 2016, Prof. Shamiss was the chief executive officer of Sheba General Hospital, the largest hospital in Israel. Prof. Shamiss also served as Vice Dean at Ben Gurion University School of Medicine from January 2017 to June 2020 and remains a Professor at the institution. Prof. Shamiss is a past Surgeon General of the Israel Air Force, Colonel (Retired).
David Tsur has served on our board of directors since our inception and serves as a member of our Strategy Committee. Mr. Tsur served as the Active Deputy Chairman on a half-time basis from July 2015 until December 31, 2019. Mr. Tsur served as our Chief Executive Officer from our inception until July 2015. Mr. Tsur currently serves as the Chairman of the Board of Directors of Kanabo Ltd. (LSE) and as a director of BioHarvest Sciences Inc. (CSE). Prior to co-founding Kamada in 1990, Mr. Tsur served as Chief Executive Officer of Arad Systems and RAD Chemicals Inc. Mr. Tsur previously served as the Chairman of the Board of Directors of CollPlant Ltd., a company listed on the TASE and OTC market. Mr. Tsur has also held various positions in the Israeli Ministry of Economy and Industry (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a B.A. degree in Economics and International Relations and an M.B.A. degree in Business Management, both from the Hebrew University of Jerusalem.
Ishay Davidi has served on our board of directors since December 2019. Mr. Davidi is the Founder and has served as Chief Executive Officer of the FIMI Opportunity Funds, Israel’s largest group of private equity funds, since 1996. Mr. Davidi currently serves as the Chairman of the Board of Directors of Hadera Paper Ltd. (TASE) and Polyram Plastic Industries Ltd (TASE). Mr. Davidi also serves as a director of Gilat Satellite Networks Ltd. (NASDAQ and TASE), Bet Shemesh Engines Ltd. (TASE), C. Mer Industries Ltd. (TASE), G1 Security Systems Ltd. (TASE), PCB Technologies Ltd. (TASE), Rekah Pharmaceutical Industries (TASE), SOS Ltd., GreenStream Ltd., Amiad Water Systems Ltd (AIM), Rimoni Industries Ltd. (TASE) and Elyakim Ben-Ari Group Ltd. Mr. Davidi previously served as the Chairman of the board of directors of Inrom, Retalix (previously traded on NASDAQ and TASE) and Tefron Ltd. (NYSE and TASE) and as a director of Pharm Up Ltd (TASE), Ham-Let Ltd. (TASE), Ormat Industries Ltd. (previously traded on TASE), Lipman Electronic Engineering Ltd. (NASDAQ and TASE), Merhav Ceramic and Building Materials Center Ltd. (NASDAQ and TASE), Orian C.M. Ltd. (TASE), Ophir Optronics Ltd., Overseas Commerce Ltd. (TASE), Scope Metals Group Ltd. (TASE), Tadir-Gan (Precision Products) 1993 Ltd. (TASE) and Formula Systems Ltd. (NASDAQ and TASE). Prior to establishing FIMI, from 1993 until 1996, Mr. Davidi was the Founder and Chief Executive Officer of Tikvah Fund, a private Israeli investment fund. From 1992 until 1993 Mr. Davidi served as the Chief Executive Officer of Zer Science Industries Ltd. Mr. Davidi holds an M.B.A. degree from Bar Ilan University, Israel, and a B.Sc. degree, with honors, in Industrial Engineering from the Tel Aviv University, Israel.
Jonathan Hahn has served on our board of directors since March 2010, and serves as the Chairman of our Strategy Committee. Mr. Hahn serves as the President and a director of Tuteur SACIFIA, where he has been since 2013. Prior to that, Mr. Hahn served as Strategic Planning Manager at Tuteur and held a business development position at Forest Laboratories, Inc., based in New York. Mr. Hahn holds a B.A. degree from San Andrés University and a M.B.A. degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.
Karnit Goldwasser serves as an independent consultant and environmental engineer for various agencies and organizations. Ms. Goldwasser is a director at Orian DB Schenker (since September 2017), Delek San Recycling Ltd. (since December 2016) and ELA Recycling Corporation (since April 2015). Ms. Goldwasser served as a director at the government-owned Environmental Services Company Ltd., as chair of the Safety Committee (2010-2016), and as a member of the Tel Aviv-Jaffa City Council, holding the environmental portfolio (2013-2016). Ms. Goldwasser also served as a director in several Tel Aviv-Jaffa municipality corporations: Dan Municipal Sanitation Association, as chair of the audit committee; Tel Aviv-Jaffa Economic Development Authority; and Ganei Yehoshua Co. Ltd. Ms. Goldwasser holds a B.Sc. degree in Environmental Engineering, focusing on chemistry, mathematics and environmental engineering, and M.Sc. degree in Civil Engineering, specializing in Hydrodynamics and Water Resources, both from the Technion – Israel Institute of Technology, and MA degree in Public Policy and Administration from the Lauder School of Government Diplomacy and Strategy, IDC Herzliya. Ms. Goldwasser also completed the Directors Program at LAHAV, School of Management, Tel Aviv University.
Leon Recanati has served on our board of directors since May 2005, as the Chairman of our board of directors from March 2013 to August 2020, and serves as the Chairman of our Compensation Committee. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. Mr. Recanati is also a board member of the following private companies: GlenRock Israel Ltd., Gov, RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., and Shavit Capital Funds. Mr. Recanati currently serves as the Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation, Clal Industries Ltd., Azorim Investment Development and Construction Co Ltd., Delek Israel Fuel Corporation and Super-Sol Ltd. Mr. Recanati also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an M.B.A. degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion – Israel Institute of Technology and Tel Aviv University.
Lilach Payorski has served on our board of directors since December 2021, and serves as the Chairman of our Audit Committee. Ms. Payorski served as the Chief Financial Officer of Stratasys Ltd (NASDAQ: SSYS), a developer and manufacturer of 3D printers and additive solutions, from January 2017 to February 2022. Prior to that, from December 2012 until December 2016, Ms. Payorski served as Senior Vice President, Corporate Finance at Stratasys. From December 2009 to December 2012, Ms. Payorski served as Head of Finance at PMC-Sierra (NASDAQ: PMCS), a company operating in the semiconductors industry, which was subsequently acquired by Microsemi Corporation. Prior to that, from March 2005 to December 2009, Ms. Payorski served as Compliance Controller at Check Point Software Technologies Ltd. (NASDAQ: CHKP), a security company. Ms. Payorski also served as corporate controller at Wind River Systems (NASDAQ: WIND), a software company, which was subsequently acquired by Intel Corporation, from June 2003 to March 2005. Earlier in her career, from March 1997 to June 2003, Ms. Payorski worked as a chartered public accountant at Ernst & Young LLP, both in Israel and later in Palo Alto, CA. Ms. Payorski currently serves as the chairman of the audit committee of Scodix Ltd (TASE: SCDX). Ms. Payorski holds a B.A. degree in Accounting and Economics from Tel Aviv University. Ms. Payorski also completed the Board of Directors and Senior Corporate Officers Program at LAHAV, School of Management, Tel Aviv University.